SIROLIMUS-BASED IMMUNOSUPPRESSION MITIGATES PROGRESSION OF CARDIAC ALLOGRAFT VASCULOPATHY AND IMPROVES CARDIAC OUTCOMES AFTER HEART TRANSPLANTATION: A SINGLE CENTER 15-YEAR FOLLOW-UP STUDY